The overarching goal of our research program is to determine how epithelial cell-derived proteins can be harnessed to mitigate the risk of acute lung injury in various settings, to ultimately reduce the burden of end-stage lung disease. We have active projects investigating lung injury due to pneumonia, and the short- and long-term consequences of ischemia-reperfusion injury occurring in the context of lung transplantation. We utilize state-of-the-art technical modalities including flow cytometry, ELISA, protein and DNA-based molecular biology, biochemistry, cell/tissue culture, fluorescence and confocal microscopy, and DNA/RNA sequencing.
We are always eager to have people join our team at multiple levels. Please look under the Opportunities section for further details and follow our work and interests on Twitter (@kulkarnilab)!
This cover image from the American Journal of Respiratory Cell and Molecular Biology demonstrates that lung specimens from subjects with end-stage cystic fibrosis (right) have increased intracellular C3 content as determined by immunofluorescence, compared to non-diseased subjects (Kulkarni et al. Intracellular C3 Protects Human Airway Epithelial Cells from Stress-associated Cell Death. PMCID: PMC6376412).